Bristol Lowers EPS Guidance On Plavix Decision
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol-Myers Squibb downgraded its full year eps guidance by up to 24% based on the impact of Apotex' launch of generic clopidogrel.